Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
Type:
Grant
Filed:
June 1, 2015
Date of Patent:
October 29, 2019
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
David M. Briscoe, Michael Klagsbrun, Sarah Bruneau, Nora Kochupurakkal, Hironao Nakayama
Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Abstract: Smooth muscle cells (SMC) from subjects carrying at least one 9p21 risk factor, can be resistant to efferocytosis, leading to the retention of such cells in the necrotic core of atherosclerotic plaque. In the methods of the invention, an agent that increases efferocytosis of cellular components of coronary plaque, including efferocytosis of apoptotic smooth muscle cells, is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
Type:
Grant
Filed:
September 15, 2014
Date of Patent:
June 25, 2019
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: A pharmaceutical formulation in a lyophilised form, which comprises pharmacologically effective amount of interferon beta-1a as an active ingredient, disaccharides as a bulking agent and a non-ionic surfactant. After reconstitution, the composition can be administered intravenously.
Type:
Grant
Filed:
November 18, 2016
Date of Patent:
May 21, 2019
Assignee:
Faron Pharmaceuticals Oy
Inventors:
Markku Jalkanen, Mikael Maksimow, Ilse Piippo
Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.
Type:
Grant
Filed:
June 5, 2017
Date of Patent:
May 7, 2019
Assignees:
AMGEN FREMONT INC., WARNER-LAMBERT COMPANY LLC
Inventors:
Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimee Kellermann, Joseph Edwin Low, James Leslie Mobley
Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.
Type:
Grant
Filed:
November 28, 2016
Date of Patent:
April 16, 2019
Assignee:
ImmunGene Inc
Inventors:
Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
Abstract: The present invention relates to the use of endocytosis inhibitors, including clathrin-dependent endocytosis inhibitors such as inhibitors of dynamin and antibodies, for enhancing the immune response to cancer, and thereby treating cancers including cancer associated receptor positive cancers.
Type:
Grant
Filed:
October 28, 2013
Date of Patent:
April 9, 2019
Assignee:
THE UNIVERSITY OF QUEENSLAND
Inventors:
Fiona Simpson, Nicholas Andrew Saunders
Abstract: This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favorable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favorable change or starts to show an unfavorable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS.
Type:
Grant
Filed:
January 22, 2014
Date of Patent:
April 2, 2019
Assignee:
FARON PHARMACEUTICALS OY
Inventors:
Mikael Maksimow, Marko Salmi, Markku Jalkanen, Sirpa Jalkanen
Abstract: Embodiments of the invention provide shaped masses (SM) comprising one or more drugs such as proteins or polypeptides and methods for forming and delivering such SM's. One embodiment provides a SM comprising a drug e.g., a protein or polypeptide having a biological activity in the body of a mammal. The SM is formed by compression of a precursor material (PM) comprising the drug wherein an amount of biologically active drug in the SM is a minimum level to that in the PM. Drugs which may be incorporated into the SM include insulin, incretins and immunoglobulins e.g., interleukin neutralizing antibodies or TNF-?-inhibiting antibodies. Embodiments of the invention are particularly useful for the oral delivery of drugs which would be degraded within the GI tract, wherein the SM containing the drug is formed as or incorporated into a tissue penetrating member which is inserted into the intestinal wall after oral ingestion.
Type:
Grant
Filed:
May 2, 2016
Date of Patent:
March 12, 2019
Assignee:
InCube Labs, LLC
Inventors:
Mir Imran, Mercedes Morales, Radhika Korupolu, Elaine To, Joel Harris, Mir Hashim
Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.
Type:
Grant
Filed:
December 11, 2015
Date of Patent:
February 26, 2019
Assignees:
ImmuPharma France SA, Centre National De La Recherche Scientifique
Inventors:
Sylviane Muller, Robert H. Zimmer, Jean-Paul Briand
Abstract: The present disclosure relates to a monoclonal antibody specifically binding to human Long Interspersed Element-1 ORF2 encoded protein (L1-ORF2p) obtained from hybridoma chA1, and derivatives and uses thereof, including for prediction of response of cancer patients to NNRTI treatments. It also relates to a method for early detection of cell transformation in pre-neoplastic tissues of a human subject, comprising detecting in cells of a pre-neoplastic tissue sample from said subject the expression of L1-ORF2p, wherein the expression of L1-ORF2p indicates the presence of cell transformation in said pre-neoplastic tissues. It also relates to a method for detecting progression of colon adenoma in a human subject suffering from colon adenoma, based on detection of an increase of L1-ORF2p expression.
Abstract: This disclosure describes polypeptides fragments of annexin II, variants thereof, compositions that includes such fragments and/or variants, and methods of using such frag and/or variants.
Abstract: Administration of an antibody that specifically binds IL-1? is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hepatitis C virus (HCV) infectious disease. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating HCV infectious disease or an antiviral composition for HCV, containing at least one selected from the group consisting of: GRIM19 protein or a fragment thereof; and a gene encoding the protein or a fragment of the protein.
Type:
Grant
Filed:
October 28, 2014
Date of Patent:
February 5, 2019
Assignee:
THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Seung Kew Yoon, Jung Hee Kim, Won Hee Hur, Mi La Cho, Jung Eun Choi, Eun Byul Lee
Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
Type:
Grant
Filed:
November 22, 2016
Date of Patent:
January 22, 2019
Assignee:
The Regents of the University of California
Inventors:
Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
Abstract: The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment.
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Type:
Grant
Filed:
February 14, 2017
Date of Patent:
January 1, 2019
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
Type:
Grant
Filed:
January 31, 2017
Date of Patent:
January 1, 2019
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LORRAINE, CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU), UNIVERSITE PARIS DIDEROT-PARIS 7, UNIVERSITE PARIS DESCARTES
Inventors:
Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad